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ABSTRACT
Dual-energy X-ray absorptiometry (DXA)-derived appendicular lean mass/height2 (ALM/ht2) is the most commonly used estimate of
musclemass in the assessment of sarcopenia, but its predictive value for fracture is substantially attenuated by femoral neck (fn) bone
mineral density (BMD). We investigated predictive value of 11 sarcopenia definitions for incident fracture, independent of fnBMD,
fracture risk assessment tool (FRAX®) probability, and prior falls, using an extension of Poisson regression in US, Sweden, and Hong
Kong Osteoporois Fractures in Men Study (MrOS) cohorts. Definitions tested were those of Baumgartner and Delmonico (ALM/ht2
only), Morley, the International Working Group on Sarcopenia, European Working Group on Sarcopenia in Older People (EWGSOP1
and 2), Asian Working Group on Sarcopenia, Foundation for the National Institutes of Health (FNIH) 1 and 2 (using ALM/body mass
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index [BMI], incorporating muscle strength and/or physical performance measures plus ALM/ht2), and Sarcopenia Definitions and
Outcomes Consortium (gait speed and grip strength). Associations were adjusted for age and time since baseline and reported as
hazard ratio (HR) for first incident fracture, here major osteoporotic fracture (MOF; clinical vertebral, hip, distal forearm, proximal
humerus). Further analyses adjusted additionally for FRAX-MOF probability (n = 7531; calculated fnBMD), prior falls (y/n), or fnBMD
T-score. Results were synthesized by meta-analysis. In 5660 men in USA, 2764 Sweden and 1987 Hong Kong (mean ages 73.5, 75.4,
and 72.4 years, respectively), sarcopenia prevalence ranged from 0.5% to 35%. Sarcopenia status, by all definitions except those of
FNIH, was associated with incident MOF (HR = 1.39 to 2.07). Associations were robust to adjustment for prior falls or FRAX probability
(without fnBMD); adjustment for fnBMD T-score attenuated associations. EWGSOP2 severe sarcopenia (incorporating chair stand
time, gait speed, and grip strength plus ALM) was most predictive, albeit at low prevalence, and appeared only modestly influenced
by inclusion of fnBMD. In conclusion, the predictive value for fracture of sarcopenia definitions based on ALM is reduced by adjust-
ment for fnBMDbut strengthened by additional inclusion of physical performancemeasures. © 2021 The Authors. Journal of Bone and
Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
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Introduction
S arcopenia (accelerated loss of muscle strength, function, andmass),(1)while now having an associated International Classi-
fication of Diseases (ICD) code, presents a diagnostic challenge,
given the current wide range of approaches to its operational
characterization. By various definitions, sarcopenia has been
associated with outcomes such as falls, fractures, and death,(1)
but it is increasingly apparent that there are limitations inherent
in these approaches resulting from dual-energy X-ray absorpti-
ometry (DXA)-derived appendicular lean mass (ALM) being a
component part.(2,3) We have recently demonstrated that the
predictive capacity of DXA ALM for incident fracture, in the three
Osteoporotic Fractures in Men (MrOS) cohorts, is attenuated to
the null by inclusion of femoral neck bone mineral density
(BMD) T-score.(4) Similar findings have been observed in the US
Health ABC(5) and WHI cohorts(6) and are recognized in recent
recommendations from the Sarcopenia Definitions and Out-
comes Consortium (SDOC).(7,8) Other than that from SDOC, cur-
rent definitions of sarcopenia incorporate DXA ALM as the
measure of muscle mass, either alone, or in the newer defini-
tions, together with measures of physical function/perfor-
mance/strength, such as gait speed and grip strength. Indeed,
the most recent European Working Group algorithm moves the
focus from ALM to that of performance/function and strength
as the important attributes.(9) Given the centrality of DXA ALM
to current sarcopenia definitions and the apparent weakness of
ALM as a predictor of incident fracture after adjustment for
BMD, an important unanswered question is whether the predic-
tive capacity for fracture of these sarcopenia definitions remains
when bone mineral density is also taken into account. Clinically,
there would seem little point in undertaking the assessments
required for sarcopenia definition (including whole-body DXA,
gait speed, and grip strength, for example) if the risk information
conveyed by the assessment tells us nothing beyond that associ-
ated with femoral neck BMD (a very quick measure to obtain).
This consideration also applies to independence from fracture
risk assessment tool (FRAX®) probability and prior history of falls.
A further unanswered question therefore relates to the magni-
tude of the risk relationships between sarcopenia definitions
and fracture outcomes with these various adjustments. Finally,
it unknown how these associations might vary by age, an impor-
tant consideration in terms of clinical impact. We therefore
undertook a meta-analysis of the three MrOS cohorts (US, Swe-
den, Hong Kong) to investigate whether the predictive value of
sarcopenia definitions for incident fracture was independent of
BMD, FRAX probability, and history of falls and to quantify the
magnitude and age dependence of these associations.
Materials and Methods
Participants
Details of the MrOS cohort studies have been published
previously,(4,10–13) but briefly, MrOS is a multicenter study of
community-dwelling men aged 65 years or older from three
international cohorts, recruited and evaluated using similar pro-
tocols. To be eligible for the study, subjects had to be able to
walk without aid. In the MrOS Hong Kong Study, 2000 Chinese
men, aged 65 to 92 years, were enrolled between August 2001
and February 2003.(14) All were Hong Kong residents of Asian
ethnicity. Stratified sampling was adopted to ensure that 33%
of subjects were included in each of the following age groups:
65 to 69, 70 to 74, and ≥75 years. Recruitment notices were
placed in housing estates and community centers for the elderly.
In the MrOS Sweden Study, 3014 men, aged 69 to 81 years, were
enrolled between October 2001 and December 2004.(12,15) The
cohort comprised men from the cities of Malmo, Gothenburg,
and Uppsala, identified and recruited using national population
registers. More than 99% were of white ethnicity. The participa-
tion rate in theMrOS Sweden Study was 45%. In theMrOS United
States study, 5994 men, aged 65 to 100 years, were enrolled at
six sites between March 2000 and April 2002.(16,17) Each US clin-
ical site designed and customized strategies to enhance recruit-
ment of its population. Common strategies included mailings
from the Department of Motor Vehicles, voter registration and
participant databases, common senior newspaper features and
advertisement, and targeted presentations. Self-defined racial/
ethnic ancestry was ascertained through questionnaires at base-
line (90% white ethnicity).
Exposure variables
The international MrOS questionnaire(16) was administered at
baseline to collect information about current smoking, number
and type of medications, fracture history, family history of hip
fracture, past medical history (rheumatoid arthritis), and high
consumption of alcohol (3 or more glasses of alcohol-containing
drinks per day), calculated from the reported frequency and
amount of alcohol use. Previous fracture at baseline was docu-
mented as all fractures after the age of 50 years, regardless of
trauma. For glucocorticoid exposure, this was documented in
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MrOS as use at least 3 times per week in the month preceding
the baseline assessment. Apart from glucocorticoid use and
rheumatoid arthritis (both FRAX input variables), there was no
information on secondary causes of osteoporosis and the “sec-
ondary osteoporosis” input variable for FRAX probability calcula-
tion was set to no for all men. Self-reported falls during the
12 months preceding the baseline were recorded by question-
naire (past falls).
At baseline, height (centimeters) and weight (kilograms) were
measured, and body mass index (BMI) was calculated as kilo-
grams per square meter. Time to complete 5 chair stands, walk-
ing speed over 6 m (at usual pace), and grip strength using
JAMAR dynamometers (Sammons Preston Rolyan, Bolingbrook,
IL, USA) were assessed at the baseline visit. Areal bone mineral
density (aBMD) was measured at the femoral neck, and appen-
dicular lean mass from whole body scans, using Hologic QDR
4500 A or W (Hologic, Bedford, MA, USA) or Lunar Prodigy
(GE Lunar Corp., Madison, WI, USA) depending on the center,
with cross-calibration of instruments for BMD. A T-score was cal-
culated using NHANES young women (white) as a reference
value.(18,19) In the subset in which the necessary variables were
available (n = 7531), FRAX 10-year probability of major osteopo-
rotic fracture (MOF: hip, proximal humerus, clinical vertebral, or
distal forearm sites) was calculated using clinical risk factors
described above with and without femoral neck BMD entered
into country-specific FRAX models.
Fracture and death outcomes
Hong Kong(20)
Incident fractures were captured via subject follow-up through
phone call or visit to the research center. All fracture sites (hip,
wrist, skull/face, ribs, shoulder, arm, wrist, vertebra, tibia, fibula,
foot, metatarsal toes, hand, fingers, and pelvis) were recorded.
Pathological fractures were excluded. Only incident fractures
reported by participants and confirmed by X-ray or medical
record review were included. Deaths were verified by death
certificates.
Sweden(21)
Central registers covering all Swedish citizens were used to
identify the subjects and the date of death for all subjects
who died during the study. For incident fracture evaluation,
the computerized X-ray archives in Malmo, Gothenborg, and
Uppsala were searched for new fractures occurring after the
baseline visit using the unique personal registration number
allocated to every Swedish citizen. If additional fractures were
reported by the study subject after the baseline visit, these
were only included if confirmed by physician review of radiol-
ogy reports.
USA(16)
Triannual questionnaires were mailed to each participant. If a
participant reported a fracture, study staff conducted a follow-
up telephone interview to determine the date the fracture had
occurred, a description of how the fracture occurred, the type
of trauma that resulted in the fracture, the participant’s location
and activities at the time of the fracture, symptoms just before or
coincident with the fracture, and source of medical care for the
fracture. All reported fractures were centrally verified by a
physician adjudicator throughmedical records. Deaths were ver-
ified through centralized review of state death certificates.
Sarcopenia definitions
Individuals were classified as sarcopenic or non-sarcopenic
according to each individual sarcopenia definition, as published
by International Working group on Sarcopenia (IWGS),(22)
Baumgartner,(23) European Working Group on Sarcopenia in
Older People (EWGSOP1),(24) Morley,(25) Delmonico,(26,27) Asian
Working Group on Sarcopenia (AWGS),(28) and the Foundation
for the National Institutes of Health (FNIH 1 and 2),(29) together
with the recently published revised EWGSOP2 guidelines, incor-
porating definitions of “confirmed” and “severe sarcopenia”,(9)
and the recent US guidelines from the Sarcopenia Definitions
and Outcomes Consortium (SDOC).(7,8) Thus, 11 sarcopenia defi-
nitions were explored as the exposure. The majority of these
guidelines use thresholds derived from expert consensus, and
all but SDOC include a measure of appendicular lean mass. In
all but the two data-driven FNIH definitions (in which appendic-
ular lean mass is divided by body mass index), this is incorpo-
rated as appendicular lean mass divided by height squared. In
the earlier definitions (Baumgartner, Delmonico, FNIH1), the
presence of sarcopenia is based solely on the measure of appen-
dicular lean mass. In later definitions (FNIH2, IWGS, EWGSOP
1 and 2, Morley, and AWGS), this is combined with the require-
ment for impaired strength or function, assessed through grip
strength, chair stand time, or gait speed. In EWGSOP2, “con-
firmed” sarcopenia is based on low DXA ALM/height2 in combi-
nation with increased chair stand time or low grip strength;
additional low gait speed constitutes severe sarcopenia. The
SDOC approach dispenses with ALM entirely. The cut points used
in the sarcopenia definitions, together with the prevalence of
each definition by cohort, are demonstrated in Table 1.
Statistical methods
Clinical outcomes comprised any fracture, osteoporotic fracture
(defined according to Kanis and colleagues(30) as clinical verte-
bral, ribs, pelvis, humerus, clavicle, scapula, sternum, hip, other
femoral fractures, tibia, fibula, distal forearm/wrist), MOF, and
hip fracture. An extension of Poisson regression models(31)
was used to study the association between the future risk of
fracture and sarcopenia, FRAX, prior falls, and BMD. All associa-
tions were adjusted for age and time since baseline. In contrast
to logistic regression, the Poisson regression uses the length of
each individual’s follow-up period and the hazard function is
assumed to be exp(β0 + β1  current time from baseline + β2 
current age + β3  variable of interest). The observation period
of each participant was divided into intervals of 1 month. One
fracture per person and time to the first fracture were counted,
and time at risk was censored at the time of first fracture, loss to
follow-up, death, or end of follow-up. Unlike a Cox model, the
Poisson model uses a data duplication method, accounting
for the competing mortality risk for fracture risk prediction.(32)
We initially investigated the predictive value of each sarcopenia
definition adjusted only for age and follow-up time. Subse-
quently, we used multivariate models to investigate the predic-
tive value of these definitions independent of FRAX, prior falls,
or BMD (entered into the model as femoral neck T-score). The
association between sarcopenia definition (yes/no) and risk of
fracture is presented as a hazard ratio (HR) together with 95%
confidence intervals (CI). Two-sided p values were used for all
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analyses and p < .05 considered to be significant. Analyses were
undertaken separately within each cohort and then the
β-coefficients from each cohort were weighted according to
the variance and merged to determine the weighted mean of
the coefficient and its standard deviation (fixed-effects meta-
analysis, since heterogeneity was low to moderate as assessed
by I2).(33) The risk ratios are then given by e(weighted mean coeffi-
cient). Finally, we investigated whether the magnitude of associ-
ations differed by age.
Results
Characteristics of participants
The study cohort consisted of 10,411 men who had information
on the key exposures, together with prior falls and femoral neck
BMD:(4) 5660 men in USA (mean age 73.5 years; mean follow-up
10.9 years); 2764 men in Sweden (mean age 75.4 years; mean
follow-up 8.7 years); and 1987 men in Hong Kong (mean age
72.4 years; mean follow-up 9.9 years) (Table 2). Previous fracture
was more commonly reported in Sweden (35%) than in the USA
(22%) and Hong Kong (14%). The frequency of past falls was sim-
ilar across the cohorts at 20%, 16%, and 15%, respectively. Con-
sistent with the known country-specific epidemiology of
fracture, the highest mean FRAX MOF probability (with BMD)
was observed in Sweden (11.4%), followed by USA (7.8%) and
Hong Kong (6.6%). Supplemental Table S1 presents the baseline
characteristics according to whether FRAX probability was avail-
able for analysis or not, demonstrating that overall, the popula-
tions with or without FRAX were similar within countries.
Proportion of cohort defined as sarcopenic by individual
definition
The proportion of the population defined as sarcopenic varied
markedly by individual definition, muchmore so than by country
cohort (Table 1). Thus, the Baumgartner definition gave the high-
est prevalence in all three cohorts (35% in Hong Kong, 22% in
Sweden, and 21% in USA). In contrast, the proportion who were
defined as sarcopenic was 10-fold or more lower using the FNIH2
definition (4% in Hong Kong, 0.4% in Sweden, and 0.9% in USA).
The EWGSOP2 severe sarcopenia definition also yielded low
prevalences: 3.6% Hong Kong, 0.6% Sweden, 0.5% USA.
Associations between sarcopenia definition and incident
fracture
In base models adjusted for age and follow-up time only, all sar-
copenia definitions other than FNIH 1 and 2 were predictive of
incident fracture across the fracture groupings. Overall, the
Baumgartner and Delmonico definitions, which are based on
ALM alone, had somewhat lower hazard ratios for fracture
(Baumgartner HR for MOF = 1.39 [95% CI 1.22–1.58] and Delmo-
nico HR = 1.40 [95% CI 1.23–1.59]) than did the definitions incor-
porating ALM and a measure of function or strength, from IWGS,
EWGSOP (1 and 2-confirmed), Morley, and AWGS, with hazard
ratios for MOF ranging from 1.60 to 1.92. The highest hazard
ratios were for the SDOC and EWGSOP2 severe sarcopenia defi-
nitions: for example, EWGSOP2 severe, MOF: HR = 2.07 (95% CI
1.28–3.33) and hip: HR = 2.40 (95% CI 1.26–4.57), albeit with rel-
atively wide confidence intervals. These associations are summa-
rized in Table 3 and Fig. 1, and representative associations by
country cohort are presented in Supplemental Table S2.
Effect of adjustment for prior falls, FRAX probability, or
femoral neck BMD T-score
Table 3 and Fig. 1 demonstrate that inclusion of prior falls or
FRAX MOF probability (calculated without or with femoral neck
BMD) in the models in addition to age and follow-up time did
not materially change themagnitude of the relationships. In con-
trast, inclusion of femoral neck BMD T-score in addition to age
and follow-up time attenuated the predictive value of sarcopenia
definitions. Indeed, the definitions of Baumgartner and Delmo-
nico, together with that of Morley, were no longer statistically
significant predictors of incident major osteoporotic fracture.
Table 1. Cut Points for Appendicular Lean Mass, Gait Speed, and Grip Strength as Incorporated in Sarcopenia Definitions and Prevalence
of Sarcopenia According to Definition and Country Cohort
















Baumgartner ≤7.26 35% 22% 21%
Delmonico ≤7.25 35% 21% 21%
FNIH 1 ALM/BMI <0.789 21% 13% 17%
IWGS ≤7.23 <1 18% 3% 4%
EWGSOP1 ≤7.26 <0.8 <30 15% 2% 4%
EWGSOP2:
confirmed
<7.0 <27 >15 10.1% 2.9% 5.5%
EWGSOP2:
severe
<7.0 ≤0.8 <27 >15 3.6% 0.6% 0.5%
SDOC <0.8 <35.5 11.2% 1.0% 1.7%
Morley ≤6.81 <1 10% 2% 2%
AWGS <7.0 <0.8 <26 10% 1.3% 2.0%
FNIH 2 ALM/BMI <0.789 <26 4% 0.4% 0.9%
ALM = appendicular leanmass; BMI = body mass index; FNIH = Foundation for the National Institutes of Health; IWGS = International Working Group on
Sarcopenia; EWGSOP = European Working Group on Sarcopenia in Older People; SDOC = Sarcopenia Definitions and Outcomes Consortium; AWGS =
Asian Working Group on Sarcopenia.
EWGSOP2 incorporates definitions of “confirmed” and “severe” sarcopenia.
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The predictive capacity of the SDOC and EWGSOP2 severe defini-
tion appeared rather less attenuated after adjustment for BMD,
such that, e.g., for EWGSOP2 severe, the hazard ratio for MOF
was 1.80 (95% CI 1.12–2.19) and for hip fracture was 2.31
(1.21–4.41).
Interaction between predictive value and age
We investigated whether the magnitude of association between
sarcopenia presence and incident fracture differed by age. There
was evidence of such an effect, summarized in Table 4, for EWG-
SOP2 confirmed definition as a representative example. Thus,
the HR ranged from 3.24 (95% CI 1.88–5.58) for major osteopo-
rotic fracture at age 70 years to 1.73 (95% CI 1.35–2.23) at
85 years, p interaction = 0.023. Results for EWGSOP2 confirmed
together with other representative definitions are presented in
Supplemental Table S3.
Discussion
In this large population of older men, uniformly assessed across
three international cohorts, we observed that sarcopenia defini-
tions other than those based on ALM divided by BMI were mod-
estly predictive of incident fractures but that this association was
attenuated when femoral neck BMD T-score was incorporated in
the regression models. The SDOC and EWGSOP2 severe sarcope-
nia definitions appeared the most predictive of fracture out-
comes but at low population prevalences. Indeed, as has been
observed elsewhere,(34) the prevalence of sarcopenia varied
10-fold or more according to individual definitions within each
country cohort, which clearly presents some practical difficulties
with the operationalization of sarcopenia definitions in clinical
practice or in their use as endpoints in clinical trials of agents
aimed at treating the condition. This variability will also have
an obvious impact on global sarcopenia epidemiology.
Our recent findings that ALM/height2, a key component of sar-
copenia definitions, is poorly predictive of incident fractures in
men and women (and even potentially a risk factor for hip frac-
tures) after adjustment for femoral neck BMD(4,35) are consistent
with previous studies in the Women’s Health Initiative (WHI). In
one analysis, WHI participants were classified into mutually
exclusive groups based on BMD and sarcopenia (dichotomous
variable according to appendicular leanmass adjusted for height
and fat mass) status.(6) Although low BMD was associated with
increased risk of hip fracture, women with sarcopenia alone
had similar hazard ratios for hip fracture to non-sarcopenic
women with normal BMD, suggesting that sarcopenia alone is
not predictive of hip fracture. In a further WHI study, appendicu-
lar lean mass was predictive of incident hip fracture among
872 participants 65 years or older who met Fried’s criteria for
frailty, but this association did not remain statistically significant
after adjusting for total hip BMD.(36)
Sarcopenia definitions of course reflect the contribution of
their constituent parts, be that appendicular lean mass alone or
together with gait speed and physical performance measures
or grip strength.(2) Evidence to date suggests that it is the appen-
dicular lean mass component, derived from DXA, which limits
the predictive capacity of sarcopenia definitions for incident
Table 2. Baseline Characteristics and Fracture Outcomes of Study Participants by Country
Hong Kong Sweden USA
Proportion of whole cohort 99% 92% 94%
n 1987 2764 5660
Person-years 19592 24102 61456
Age (years), mean (range) 72.4 (65–92) 75.4 (70–81) 73.5 (64–100)
Body mass index 23.5  3.1 26.3  3.5 27.4  3.8
Previous fracture 14% 35% 22%
Family history hip fracture 5% 13% 17%
Smoker 12% 8% 3%
Glucocorticoids 1% 2% 2%
Rheumatoid arthritis 1% 1% 5%
Excess alcohol 1% 2% 4%
BMD FN T-score −1.4  0.9 −0.9  1.0 −0.6  1.1
Gait speed (m/s) 1.0  0.2 1.3  0.3 1.2  0.2
Prior falls 15% 16% 20%
Grip strength (kg) 33.9  6.7 43.1  7.8 41.8  8.4
ALM (kg) 20.2  2.8 24.3  3.2 24.3  3.5
Height (cm) 163  5.7 175  6.5 174  6.8
ALM/height2 7.6  0.9 7.9  0.8 8.0  0.9
FRAX MOF without BMD 6.9  2.9 13.5  6.1 9.1  4.8
FRAX hip without BMD 3.4  2.5 7.5  5.5 3.6  3.9
FRAX MOF with BMD 6.6  3.2 11.4  6.7 7.8  4.6
FRAX hip with BMD 3.0  2.6 (n = 1661) 5.5  6.0 (n = 1732) 2.4  3.4 (n = 4138)
Follow-up, hip fx (years), mean (SD) 9.9 (2.8) 8.7 (2.9) 10.9 (3.8)
Any fx 11% 22% 19%
Osteoporotic fx 9% 19% 15%
MOF fx 7% 16% 10%
Hip fx 3% 7% 4%
BMD = bone mineral density; FN = femoral neck; ALM = appendicular lean mass; MOF = major osteoporotic fracture; fx = fracture.
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Table 3. Association Between Sarcopenia Definition and Incident Fractures
Exposure (Y/N) Adjustment Any fx Ost fx MOF fx Hip fx
Baumgartner Age, FU time 1.29 (1.16, 1.42) 1.31 (1.17, 1.47) 1.39 (1.22, 1.58) 1.52 (1.24, 1.85)
+ prior falls 1.28 (1.16, 1.42) 1.29 (1.16, 1.45) 1.38 (1.21, 1.57) 1.51 (1.24, 1.84)
or + FRAX wo BMD 1.23 (1.08, 1.39) 1.28 (1.11, 1.47) 1.38 (1.18, 1.62) 1.51 (1.19, 1.92)
or + FRAX with BMD 1.20 (1.06, 1.35) 1.25 (1.09, 1.43) 1.34 (1.15, 1.57) 1.42 (1.12, 1.79)
or + FN BMD 1.04 (0.94, 1.15) 1.02 (0.91, 1.15) 1.05 (0.92, 1.20) 1.01 (0.82, 1.23)
Delmonico Age, FU time 1.31 (1.18, 1.45) 1.29 (1.13, 1.46) 1.40 (1.23, 1.59) 1.55 (1.28, 1.89)
+ prior falls 1.30 (1.18, 1.44) 1.31 (1.17, 1.47) 1.39 (1.23, 1.59) 1.55 (1.27, 1.89)
or + FRAX wo BMD 1.24 (1.10, 1.41) 1.30 (1.13, 1.50) 1.40 (1.19, 1.63) 1.56 (1.23, 1.97)
or + FRAX with BMD 1.22 (1.08, 1.38) 1.27 (1.10, 1.46) 1.35 (1.15, 1.58) 1.45 (1.15, 1.84)
or + FN BMD 1.06 (0.96, 1.18) 1.04 (0.93, 1.17) 1.06 (0.93, 1.22) 1.03 (0.85, 1.26)
FNIH 1 Age, FU time 1.04 (0.92, 1.17) 1.01 (0.88, 1.15) 1.01 (0.87, 1.19) 0.81 (0.62, 1.05)
+ prior falls 1.02 (0.91, 1.15) 1.00 (0.87, 1.14) 1.00 (0.86, 1.17) 0.80 (0.62, 1.04)
or + FRAX wo BMD 1.10 (0.94, 1.28) 1.01 (0.85, 1.20) 1.00 (0.83, 1.22) 0.73 (0.53, 1.01)
or + FRAX with BMD 1.05 (0.91, 1.21) 0.96 (0.81, 1.14) 0.96 (0.79, 1.17) 0.73 (0.53, 1.00)
or + FN BMD 1.06 (0.94, 1.20) 1.04 (0.90, 1.19) 1.04 (0.89, 1.21) 0.84 (0.65, 1.08)
FNIH 2 Age, FU time 1.13 (0.75, 1.70) 1.10 (0.70, 1.74) 1.01 (0.58, 1.76) 0.87 (0.38, 2.00)
+ prior falls 1.11 (0.73, 1.67) 1.09 (0.68, 1.72) 0.99 (0.57, 1.72) 0.86 (0.37, 1.98)
or + FRAX wo BMD 1.02 (0.61, 1.73) 1.06 (0.59, 1.88) 1.07 (0.55, 2.08) 1.33 (0.48, 3.70)
or + FRAX with BMD 1.01 (0.60, 1.69) 1.05 (0.58, 1.88) 1.08 (0.55, 2.10) 1.34 (0.50, 3.93)
or + FN BMD 1.06 (0.71, 1.59) 1.05 (0.66, 1.66) 0.95 (0.55, 1.64) 0.85 (0.37, 1.95)
IWGS Age, FU time 1.39 (1.15, 1.68) 1.41 (1.15, 1.74) 1.60 (1.27, 2.01) 1.97 (1.42, 2.73)
+ prior falls 1.37 (1.14, 1.66) 1.41 (1.14, 1.74) 1.59 (1.26, 1.99) 1.96 (1.42, 2.71)
or + FRAX wo BMD 1.50 (1.20, 1.87) 1.54 (1.20, 1.97) 1.67 (1.27, 2.19) 1.89 (1.28, 2.80)
or + FRAX with BMD 1.46 (1.17, 1.83) 1.50 (1.17, 1.92) 1.62 (1.23, 2.14) 1.87 (1.26, 2.77)
or + FN BMD 1.15 (0.95, 1.39) 1.13 (0.91, 1.39) 1.24 (0.98, 1.56) 1.39 (1.00, 1.93)
EWGSOP 1 Age, FU time 1.58 (1.29, 1.92) 1.72 (1.39, 2.14) 1.76 (1.38, 2.26) 1.76 (1.21, 2.58)
+ prior falls 1.54 (1.26, 1.88) 1.69 (1.36, 2.11) 1.73 (1.35, 2.22) 1.74 (1.19, 2.55)
or + FRAX wo BMD 1.50 (1.17, 1.92) 1.65 (1.26, 2.15) 1.65 (1.21, 2.25) 1.70 (1.02, 2.80)
or + FRAX with BMD 1.51 (1.18, 1.93) 1.66 (1.27, 2.16) 1.66 (1.22, 2.25) 1.71 (1.04, 2.82)
or + FN BMD 1.29 (1.06, 1.58) 1.36 (1.09, 1.69) 1.34 (1.04, 1.73) 1.18 (0.80, 1.75)
EWGSOP2: confirmed Age, FU time 1.63 (1.35, 1.96) 1.73 (1.42, 2.11) 1.82 (1.46, 2.27) 1.89 (1.37, 2.62)
+ prior falls 1.57 (1.30, 1.90) 1.69 (1.38, 2.06) 1.76 (1.41, 2.20) 1.85 (1.34, 2.56)
or + FRAX wo BMD 1.53 (1.21, 1.93) 1.61 (1.25, 2.08) 1.65 (1.24, 2.19) 1.58 (1.03, 2.42)
or + FRAX with BMD 1.50 (1.18, 1.89) 1.58 (1.23, 2.03) 1.63 (1.22, 2.19) 1.55 (1.02, 2.36)
or + FN BMD 1.31 (1.08, 1.58) 1.35 (1.10, 1.65) 1.39 (1.11, 1.75) 1.29 (0.93, 1.80)
EWGSOP2: severe Age, FU time 1.70 (1.12, 2.57) 1.92 (1.24, 2.99) 2.07 (1.28, 3.33) 2.40 (1.26, 4.57)
+ prior falls 1.68 (1.11, 2.56) 1.89 (1.22, 2.94) 2.01 (1.25, 3.24) 2.33 (1.22, 4.44)
or + FRAX wo BMD 2.10 (1.28, 3.41) 2.28 (1.35, 3.86) 2.21 (1.22, 3.98) 1.76 (0.69, 4.47)
or + FRAX with BMD 2.25 (1.38, 3.67) 2.43 (1.46, 4.16) 2.43 (1.35, 4.38) 2.14 (0.84, 5.43)
or + FN BMD 1.55 (1.02, 2.36) 1.71 (1.10, 2.66) 1.80 (1.12, 2.91) 2.31 (1.21, 4.41)
SDOC Age, FU time 1.57(1.21, 2.03) 1.67 (1.26, 2.22) 1.51 (1.09, 2.11) 2.48 (1.64, 3.76)
+ prior falls 1.51 (1.16, 1.96) 1.62 (1.22, 2.15) 1.46 (1.05, 2.03) 2.39 (1.58, 3.63)
or + FRAX wo BMD 1.93 (1.44, 2.58) 2.05 (1.49, 2.82) 1.76 (1.20, 2.58) 2.47 (1.48, 4.15)
or + FRAX with BMD 1.88 (1.41, 2.52) 2.01 (1.46, 2.76) 1.73 (1.18, 2.53) 2.55 (1.53, 4.25)
or + FN BMD 1.52 (1.147, 1.96) 1.60 (1.21, 2.12) 1.43 (1.03, 1.99) 2.36 (1.57, 3.56)
Morley Age, FU time 1.54 (1.19, 1.98) 1.52 (1.15, 2.02) 1.74 (1.29, 2.36) 1.82 (1.16, 2.84)
+ prior falls 1.53 (1.19, 1.97) 1.51 (1.14, 2.01) 1.73 (1.28, 2.33) 1.83 (1.17, 2.85)
or + FRAX wo BMD 1.73 (1.29, 2.31) 1.65 (1.18, 2.30) 1.80 (1.26, 2.59) 1.72 (0.99, 2.97
or + FRAX with BMD 1.63 (1.21, 2.19) 1.54 (1.10, 2.15) 1.68 (1.16, 2.42) 1.65 (0.96, 2.85)
or + FN BMD 1.20 (0.93, 1.55) 1.12 (0.84, 1.48) 1.24 (0.91, 1.69) 1.18 (0.75, 1.87)
AWGS Age, FU time 1.73 (1.36, 2.20) 1.83 (1.41, 2.38) 1.92 (1.43, 2.57) 2.17 (1.41, 3.34)
+ prior falls 1.68 (1.31, 2.14) 1.78 (1.37, 2.32) 1.87 (1.39, 2.51) 2.13 (1.38, 3.28)
or + FRAX wo BMD 1.71 (1.27 2.30) 1.78 (1.31, 2.41) 1.86 (1.29, 2.69) 2.04 (1.15, 3.64)
or + FRAX with BMD 1.74 (1.30, 2.35) 1.87 (1.35, 2.59) 1.93 (1.33, 2.78) 2.23 (1.26, 3.95)
or + FN BMD 1.47 (1.15, 1.88) 1.52 (1.17, 1.98) 1.54 (1.15, 2.07) 1.60 (1.03, 2.49)
Fx = fracture; Ost = osteoporotic; MOF = major osteoporotic fracture; FU = follow-up; wo = without; BMD = bone mineral density; FN = femoral neck;
FNIH = Foundation for the National Institutes of Health; IWGS = International Working Group on Sarcopenia; EWGSOP = European Working Group on Sar-
copenia in Older People; SDOC = Sarcopenia Definitions and Outcomes Consortium; AWGS = Asian Working Group on Sarcopenia.
Models are presented adjusted for age and follow-up time alone and then additionally for either prior falls, FRAX MOF probability without BMD, FRAXMOF
probability with BMD, or femoral neck BMD T-score. Associations with p < .05 are in bold. n = 10,411 except for +FRAX with and without BMD (n = 7531).
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fracture, particularly when femoral neck BMD T-score is also
included.(2) Thus, we demonstrated in MrOS that DXA ALM is
modestly predictive of incident fracture independently of past
falls and FRAX probability.(4)However, the relationship wasmark-
edly attenuated by the addition of femoral neck BMD T-score,
and indeed greater ALM (or ALM/ht2) appeared to be a risk factor
for hip fracture after accounting for femoral neck BMD. A similar
finding was observed in the Health ABC study,(5) with the find-
ings possibly suggesting that muscle mass in excess of bone
mass might be a pro-fracture state. However, this would seem
to be at odds with the general adaptation of bone to
muscle,(37) and excess muscle mass or power over bone strength
seems unlikely in older men (compared with younger athletes,
for example). Similar findings come from the Framingham
study,(38) although in the Swiss GERICO study adjustment of
low lean mass for BMD did not substantially attenuate associa-
tions with incident fracture,(39) and differential patterns by sex
have been noted elsewhere.(7)
Fig 1. Associations between sarcopenia definitions (IWGS, EWGSOP2 “confirmed,” AWGS, and SDOC) and risk of incident major osteoporotic fracture.
Data shown are the point estimate for the hazard ratio (sarcopenia yes/no) and 95% confidence interval. Models are presented adjusted for age and
follow-up time alone and then additionally for either prior falls, FRAX major osteoporotic fracture (MOF) probability without bone mineral density
(BMD), FRAX MOF probability with BMD, or femoral neck BMD T-score.
Table 4. Hazard Ratios for Incident Major Osteoporotic Fracture for EWGSOP2 Confirmed Definition (Y/N) by Age Band, With p Value for
Sarcopenia × Age Interaction
Age HR (95% CI)
Adjusted for Age, FU time + prior fall Or + FRAX wo BMD Or + FRAX with BMD Or + BMD
70 years 3.24 (1.88, 5.58) 3.14 (1.82, 5.43) 3.02 (1.54, 5.93) 2.37 (1.20, 4.66) 2.19 (1.27, 3.78)
75 years 2.56 (1.76, 3.74) 2.49 (1.71, 3.63) 2.41 (1.51, 3.85) 2.03 (1.28, 3.23) 1.82 (1.24, 2.66)
80 years 2.04 (1.59, 2.60) 1.98 (1.55, 2.53) 1.89 (1.39, 2.58) 1.71 (1.26, 2.33) 1.71 (1.30, 2.25)
85 years 1.73 (1.35, 2.23) 1.69 (1.31, 2.17) 1.53 (1.11, 2.12) 1.49 (1.08, 2.05) 1.29 (1.00, 1.67)
p-interaction 0.023 0.024 0.070 0.22 0.049
HR = hazard ratio; CI = confidence interval; FU = follow-up; BMD = bone mineral density.
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The reason for this limited value of DXA appendicular lean
mass in the prediction of fracture, and indeed in the prediction
of other outcomes such as falls and mortality, may reflect several
potential factors.(2) First, ALM is not a direct measure of muscle
itself but reflects all of the non-fat, non-bone tissue within the
body.(40) Second, it is derived from the same measurement
instrument as femoral neck BMD; the body composition equa-
tions incorporate two compartments to solve the third, meaning
that a mathematical relationship between lean mass and BMD is
inevitable.(40) Third, there is a clear biological relationship
betweenmuscle and bone, elegantly laid out in themechanostat
hypothesis.(37) Thus, there is the potential for ALM to act as a sur-
rogate for BMD if this relationship is not considered. Indeed, in
our recent analysis of the MrOS cohort, measures of physical per-
formance such as gait speed and chair stand time, together with
grip strength, appeared to be rather more robust predictors of
incident fracture than did DXA ALM,(4) supporting the notion
that it is the non-DXA components of the more recent sarcope-
nia definitions that drive relationships with incident fracture.
Other studies have similarly demonstrated the greater predictive
capacity of physical function over DXA ALM as an estimate of
muscle mass.(41–45)
Taken together, these findings suggest that alternative mea-
sures of muscle, such as creatine dilution(46) or muscle cross-
sectional area or density from (p)QCT,(47–49) may offer a more
useful measure on which to base sarcopenia definitions. These
notions have been recognized in the recently revised guidelines
from the US Sarcopenia Definitions and Outcomes Consortium,
which dispenses with ALM completely, and from the European
Working Group on Sarcopenia in Older People (EWGSOP2),
which incorporates muscle strength rather than mass as the ini-
tial assessment, with the latter assessable via a range of mea-
sures rather than simply DXA ALM.(50) Of note is that the
resulting SDOC and EWGSOP2 severe sarcopenia definitions
within this revised guidance were associated with the greatest
magnitude of association with incident fracture outcomes in
our analyses and that these associations were only modestly
attenuated by incorporation of femoral neck BMD T-score. The
EWGSOP2 cut-offs for ALM/height2, gait speed, and grip strength
were similar to those used in the AWGS definition (which is, of
course, predicated on the generally smaller body size in the
Asian population), and for grip strength, in the FNIH2 definition,
but differs in the incorporation of chair stand time (previously
shown to predict fracture risk(4,44)) from AWGS and in use of
ALM/ht2 rather than ALM/BMI from FNIH2. It is therefore likely
that this additional functional component reduces the attenuat-
ing effect of BMD, but this apparent advantage must be taken in
the context of the very low population prevalence of sarcopenia
using these criteria. It is notable that adjustment for FRAX prob-
ability calculatedwith inclusion of femoral neck BMDhad amuch
less obvious influence on these associations. Although this may
at first sight appear surprising, it is important to recognize that
femoral neck BMD T-score is a very different construct to FRAX
probability calculated with BMD as one of several input variables,
all interlinked through a multivariate structure and generating a
probability over 10 years, which synthesizes risk of fracture with
risk of death.
The evidence of an age interaction (illustrated for the EWG-
SOP2 definition in Table 4, and for other definitions in Supple-
mental Table S3) suggests that sarcopenia is actually more
predictive of fracture at younger compared with older ages,
although given the potential for healthy selection bias in cohorts,
it is possible that a less marked pattern would be observed in a
completely unselected general population. Importantly, the
Poisson model uses a data duplication approach that accounts
for the competing hazard of mortality, thus reducing the likeli-
hood that this finding is simply attributable to higher mortality
at older ages. Although this may lessen the clinical impact of
such definitions in the populations at highest risk, this observa-
tion is similar to the age patterns documented with many risk
factors; essentially, occurrence of a risk factor becomes less
unusual compared with general population as age increases.
The perhaps more pertinent clinical implication arises in the
markedly diverse range of prevalences according to definition
and country cohort. Clearly a definition that detects less
than 0.5% of the population as having the condition of interest
is likely to have very limited impact on health care, a notion that
seems rather at odds with the widespread recognition of the
increasingly elderly and frail populations in many countries
globally.(51)
We studied three well-characterized cohorts drawn from gen-
eral populations with standardized assessments and prospective
recording of fractures. However, there are some limitations that
should be considered in the interpretation of our findings.(16)
First, the population studied was exclusively male, and of a mod-
est age range (64 to 99 years), so limiting generalizability of our
findings. Second, we were limited to DXAmeasures of leanmass,
so that both lean and bone measures were obtained from the
same scanner and DXA only approximates muscle mass. Third,
comparison of predictive value would ideally compare expo-
sures with similar prevalence in the population. Because the sar-
copenia definitions were dichotomous, this was clearly not
feasible, and it is therefore possible that some of the difference
in the effect size between definitions was determined by the dif-
ferences in prevalence. Indeed, it is notable, however, that pat-
terns for the EWGSOP2 confirmed, Morley, and AWGS, which
were all of similar prevalence, were broadly similar. Fourth, there
was no information on causes of secondary osteoporosis (other
than rheumatoid arthritis and glucocorticoids), and this variable
was therefore set to null. The effect of these considerations on
our findings is uncertain but may have led to an underestimation
of risk by FRAX. Finally, the definition of glucocorticoid use dif-
fered from those usually specified for incorporation into FRAX.
In conclusion, we have demonstrated novel findings that sar-
copenia definitions based on appendicular lean mass corrected
for height squared, but not corrected for BMI, are modestly pre-
dictive of incident fracture after adjustment for FRAX probability
and more so for those definitions also incorporating measures of
physical performance and/or muscle strength. The predictive
value of such definitions may vary with age and is attenuated
to different degrees by the inclusion of femoral neck BMD T-
score. This latter observation is consistent with numerous obser-
vations suggesting the limited value of DXA appendicular lean
mass as a measure of muscle in fracture risk assessment but
has not been quantified previously. Our findings thus support
the inclusion of physical performance measures in the assess-
ment of sarcopenia and also the investigation of alternativemea-
sures of muscle such as creatine dilution and pQCT, which may
prove to be more usefully incorporated into sarcopenia defini-
tions, at least in the context of predicting incident fractures.
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